Amendolara, Alfred

Anwar, Marryam

Cunningham, Braden

Edwards, Kailee

Gonzales, Jon

Jogin, Roshni

Kriak, John A

Magoffin, Wyatt

Paul, Amar

Payne, Andrew

Perry, Ryan

Pike, James

Sant, David W

Seamons, Mary

Swallow, Nathan

Tung, Steven

English

eCommons at Roseman University

Heterodyned Whole-Body Vibration Ameliorates Anxiety in Opioid-Use DisorderKailee Edwards*, Braden Cunningham*, Alfred Amendolara, Marryam Anwar, Jon Gonzales, Roshni Jogin, Wyatt Magoffin, Amar Paul, Ryan Perry, James Pike, Nathan Swallow, Steven Tung, Mary Seamons, Andrew Payne PhD, John Kriak PharmD, David Sant PhD, Kyle Bills DC, PhD1Department of Biomedical Sciences, Noorda College of Osteopathic Medicine, Provo, UT *Authors Contributed EquallyOpioid use disorder (OUD) is a rising problem in the United States and around the world, with pain and stress being major factors for initial drug seeking and relapse. The mesolimbic dopamine (DA) in the striatum is an important nexus for the rewarding properties of opioids and other addictive drugs and is strongly implicated in OUD. This study uses a novel heterodyned whole-body vibration (HWBV) device consisting of two independent vibration sources vibrating at different frequencies to treat anxiety/craving associated with OUD.BackgroundConclusionsPicture 1. Stock image from Dreamstimerepresenting different forms of opiates.Figure 3. HbA1c scoresMethodsWe evaluated 50 patients experiencing anxiety associated with OUD.  Twenty-five received HWBV treatment and 25 received a sham treatment.  Patients were treated 5 times per week for 10 minutes per day for 4-weeks.  Pre-and post-EEG and neuropsychological evaluations were performed.  Daily acute anxiety scores were taken, and weekly HAM-A anxiety scales were performed. Results ContinuedConclusionThis neurocognitive pattern is consistent with long-reported clinician reported observation of chronic migraine patients with high functioning neurocognitive profiles with targeted deficits in effecting memory and emotional affective circuits.  These data could provide additional details regarding the role of chronic migraine in neuropsychiatric disorders and possibly provide further insight into prophylaxis and treatment options. However, further research is needed. ResultsHAM-A scores were significantly reduced in the treatment group when compared to sham (-12.06 versus -3.56; n=50; p=0.0018).  Additionally, improvements were noted in Mental Rotations, Grammatical Reasoning and Response Inhibition.  Finally, significant positive changes were found in frontal alpha balance on EEG. Figure 4. Neurocognitive Scores Before and After Treatment. Changes in patient scores from before to after treatment for migraines. Gray bars represent before treatment, pink bars represent after treatment. Figure 3. Daily Anxiety Score averages (out of10) by week. All p-values are T-Tests against theintake. Day 1 = 0.057, all others were less than0.0033. Notice the increase in Week 2 Day 1and Week 4 Day 1, right after the weekends. Isuspect this is related to not using the chair onweekends.Figure 1. Hamilton Anxiety Score averages byweek. All p-values are T-Tests against the intake.Week 1= 0.093, week 2 = 0.006787, Week 3 =0.002191, Week 4 = 8.62e-05Figure 2. Clinical Opiate Withdrawal ScaleScore averages by week. All p-values are T-Tests against the intake. Week 1= 0.074,Week 2 = 0.152, Week 3 = 0.064, Week 4 =0.00836

Heterodyned Whole-Body Vibration Ameliorates Anxiety in Opioid-Use Disorder

https://ecommons.roseman.edu/cgi/viewcontent.cgi?article=1288&context=researchsymposium

Heterodyned Whole-Body Vibration Ameliorates Anxiety in Opioid-Use Disorder

Abstract

Similar works

Full text

Available Versions

eCommons at Roseman University